0001144204-16-095773.txt : 20160422 0001144204-16-095773.hdr.sgml : 20160422 20160422143234 ACCESSION NUMBER: 0001144204-16-095773 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160422 DATE AS OF CHANGE: 20160422 EFFECTIVENESS DATE: 20160422 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Atrinsic, Inc. CENTRAL INDEX KEY: 0001022899 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 061390025 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-257945 FILM NUMBER: 161586386 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: (212) 994-8200 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: NEW MOTION, INC. DATE OF NAME CHANGE: 20070504 FORMER COMPANY: FORMER CONFORMED NAME: MPLC, Inc. DATE OF NAME CHANGE: 20050608 FORMER COMPANY: FORMER CONFORMED NAME: MILLBROOK PRESS INC DATE OF NAME CHANGE: 19961022 D/A 1 primary_doc.xml X0707 D/A LIVE 0001022899 Atrinsic, Inc. 149 FIFTH AVENUE SUITE 500 NEW YORK NY NEW YORK 10010 (212) 994-8200 DELAWARE MPLC, INC. MILLBROOK PRESS INC. NEW MOTION, INC. MPLC, Inc. MILLBROOK PRESS INC Corporation true Garo H. Armen 149 Fifth Avenue Suite 500 New York NY NEW YORK 10010 Executive Officer Director Robert B. Stein 149 Fifth Avenue Suite 500 New York NY NEW YORK 10010 Director Khalil Barrage 149 Fifth Avenue Suite 500 New York NY NEW YORK 10010 Director Gregory H. Ekizian 149 Fifth Avenue Suite 500 New York NY NEW YORK 10010 Director Alexander K. Arrow 149 Fifth Avenue Suite 500 New York NY NEW YORK 10010 Executive Officer Joshua Silverman 149 Fifth Avenue Suite 500 New York NY NEW YORK 10010 Director Biotechnology Decline to Disclose 06b true 0001209191-16-101173 2016-02-12 false true true At closing, our wholly-owned subsidiary merged with and into Protagenic Therapeutics, Inc. ("PTI"), with PTI surviving the merger. Among other merger consideration issued to PTI security holders, PTI stockholders received shares of our stock. 0 Katalyst Securities LLC 112494 None None 15 MAIDEN LANE ROOM 601 NEW YORK NY NEW YORK 10038 All States false WestPark Capital, Inc. 39914 None None 1900 AVENUE OF THE STARS SUITE 310 LOS ANGELES CA CALIFORNIA 90067 All States false 5500000 5135575 364425 Includes over-allotment option and includes securities issued in exchange for payoff of $500,000.00 in debt. false 49 174183 0 Placement Agents are entitled to receive 10% cash fees for all equity raised by the Placement Agents during the offering, plus a total of $15,000 for legal fees. Does not include warrants issuable to Placement Agents. 0 false Atrinsic, Inc. /s/ Alexander K. Arrow Alexander K. Arrow Chief Financial Officer 2016-04-22